Drug Reverses Liver Scarring in Mouse Study
Pegozafermin, an FGF21 analog already in phase 3 trials, reduced fibrosis and showed signs of regressing cirrhosis in mice.
Global Weight Loss News
Reporting here follows weight management and obesity — GLP-1 drug trial and approval data, obesity rate trends, diet intervention research, weight loss surgery outcomes and the cultural conversations about body weight that generate news beyond the clinical literature. Coverage spans the science and the social.
Recent news
November 5, 2026
MetaVia Drug Cuts Liver Fat, Body WeightA phase 1 trial of DA-1726 showed reductions in liver fat and body weight in adults with obesity.
November 5, 2026
Experimental Injection Targets Deep Belly FatTwo clinical trials of CBL-514, an injectable compound that triggers fat cell death, have reported early results on abdominal fat.
November 4, 2026
Vitamin D Drug Reverses Fat Loss in Aging MiceResearchers led by Professor Chuanmao Zhang found calcipotriol restored subcutaneous fat in mice with progeria.
November 4, 2026
Fat-Free Mass Linked to Metabolic Syndrome RiskA study of 59,269 UK Biobank participants found that higher fat-free mass was associated with greater metabolic syndrome prevalence.
November 3, 2026
Pfizer Launches Ecnoglutide Weight Loss Drug in ChinaPfizer is commercializing a GLP-1 drug licensed from Sciwind Biosciences in a market it chose ahead of the United States.
November 3, 2026
Clinicians Battle GLP-1 Weight Loss MisinformationMost clinicians correct false claims about GLP-1 drugs weekly, with social media cited as a major source.
November 2, 2026
Weight Loss in Early 50s Linked to Better Heart HealthA new study suggests that losing weight in middle age may slow the worsening of blood pressure, cholesterol, and inflammation markers later in life.
November 2, 2026
Semaglutide Leads Weight Loss in Schizophrenia PatientsA network meta-analysis of 95 trials ranks GLP-1 drugs highest for weight loss among antipsychotic-treated patients with schizophrenia.
November 2, 2026
Drugmakers Race to Develop Six New Weight-Loss DrugsMajor pharmaceutical companies are advancing a pipeline of new obesity treatments as demand for GLP-1 drugs continues to grow.
November 2, 2026
Testosterone Therapy Protects Bones in Prader-Willi BoysA real-world study of 59 males with Prader-Willi syndrome links testosterone treatment to maintained bone density and higher lean mass.
More in Weight Loss
The beat runs across GLP-1 and other drug approval and effectiveness data, obesity prevalence reports, diet and lifestyle intervention study results, weight loss surgery long-term outcome research, clinical guideline updates and the cultural, policy and insurance coverage debates that have grown as pharmacological treatments have changed what weight management looks like. GLP-1 drugs have restructured coverage of weight loss more thoroughly than any development in decades, generating pharmaceutical, insurance, clinical and cultural stories simultaneously and sustaining a reporting volume that shows no sign of declining as new indications, formulations and access questions continue to emerge. Obesity prevalence data gives weight loss coverage a public health dimension that connects individual treatment stories to population-level trends in nutrition, physical activity, food environment and socioeconomic conditions. Insurance coverage decisions for weight loss treatments — which plans cover which drugs and procedures, and under what conditions — have become a significant source of coverage because they determine access for the large population for whom clinical options now exist but may not be affordable.